Biochemical Recurrent Prostate Cancer
3 clinical trials · Condition
◉ Watch Biochemical Recurrent Prostate Cancer
| Record | Firm | Date |
|---|---|---|
| MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer (NCT04876755) | Matrix Biomed, Inc. | 2021-05-30 |
| Radium-223 in Biochemically Recurrent Prostate Cancer (NCT04206319) | National Cancer Institute (NCI) | 2020-09-22 |
| Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer (NCT00596895) | University of Florida | 2003-11-01 |
Track Biochemical Recurrent Prostate Cancer automatically
Every clearance here is in the API, with alerts when new ones post.